In some examples, method for automatically computing a blood input function for dynamic positron emission tomography (PET) includes obtaining dynamic PET image data sets comprising volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals. The method includes utilizing an artificial neural network (ANN) to segment the dynamic PET image data sets displaying one or more blood vessels in the target site. The method includes automatically deriving, using the ANN, a blood input function (I D I F) based on radioactive tracer concentrations measured in one or more segments of the plurality of dynamic PET image data sets. The method includes computing a predictive model-corrected blood input function (MCIF) using time activity curve input associated with the automatically derived IDIF.
Provided are composition that include stable TLR4 agonist (e.g., KDO2) containing nanoliposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome include a lipid component comprising, consisting essentially of, or consisting of DSPC, DOPE, PEG(2000)-PE, one or more TLR4 agonists (e.g., KDO2), Cholesterol, Rhodamine or DiD, and optionally DOTAP and/or DHP. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposomes are cationic, anionic, or neutral liposomes. In some embodiments, the TLR4 agonist (e.g., KDO2) containing nanoliposome encapsulate one or more immunogenic peptides, which can be peptides associated with malignant melanoma, which optionally can be subsequences of tyrosinase, gplOO, MAGE-1,2,3,6, Melan-A/MART-1, and/or MAGE-3. Also provided are methods for treating and/or preventing malignant melanoma and for inducing anti-melanoma immune responses in subjects using the presently disclosed compositions.
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (USA)
UNIVERSITY OF MARYLAND, COLLEGE PARK (USA)
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
UNIVERSITY OF SOUTH CAROLINA (USA)
Inventor
Hobart, Karl D.
Anderson, Travis J.
Tadjer, Marko J.
Jacobs, Alan G.
Graham, Samuel
Aller, Henry
Hopkins, Patrick
Goorsky, Mark
Khan, Asif
Feygelson, Tatyana I.
Pate, Bradford B.
Abstract
In one aspect, the disclosure relates to a device comprising a plurality of semiconductor layers; a phonon bridge layer formed on the plurality of semiconductor layers; a gate electrode set into the phonon bridge layer and in contact with a surface of the plurality of semiconductor layers; and a diamond layer formed over the phonon bridge layer. The phonon bridge layer can include materials that have a speed of sound in-between the speed of sound for the diamond layer and the speed of sound of the semiconductor layer that is in contact with the phonon bridge layer. In one aspect, the device is a transistor, such as a high electron mobility transistor. The disclosure, in another aspect, relates to methods of making the devices as disclosed herein.
H01L 21/28 - Manufacture of electrodes on semiconductor bodies using processes or apparatus not provided for in groups
H10D 62/83 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group IV materials, e.g. B-doped Si or undoped Ge
H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
H01L 23/373 - Cooling facilitated by selection of materials for the device
In one aspect, the disclosure relates to a process for acrylonitrile manufacture using forced dynamic operation over transition metal promoted bismuth molybdate-based catalysts. The forced dynamic operation leverages catalyst lattice oxygen in ammoxidation of propene to improved acrylonitrile productivity and yield. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
C07C 253/26 - Preparation of carboxylic acid nitriles by ammoxidation of hydrocarbons or substituted hydrocarbons containing carbon-to-carbon multiple bonds, e.g. unsaturated aldehydes
The present disclosure relates to compositions and methods related to modification of trichome density and transport of metabolite and their uses in plants, including tobacco and cannabis. The provided transcription factors enable the increase in trichome density in plants.
A universal heart port, in various embodiments, comprises: a cylindrical heart port body defining a circular top surface, an outer surface, and a cylindrical opening that extends through the heart port body; and one or more adapter coupling flanges, each respective adapter coupling flange of the one or more adapter coupling flanges extending radially outward along at least a portion of the top surface of the heart port body and comprising a respective end stop portion that extends perpendicularly downward from a respective end portion of the respective adapter coupling flange. In some embodiments, each of the adapter coupling flanges are substantially evenly spaced about the outer surface of the heart port body. In some embodiments, the heart port further comprises one or more adapters configured for selective coupling to the heart port. The adapters may include a plug, a canula adapter, an LVAD adapter, etc.
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventor
Bart-Smith, Hilary
Loth, Eric
Zhu, Joseph Jianzhong
Moored, Keith W.
Mivehchi, Amin
Zuo, Lei
Bacelli, Giorgio
Keow, Alicia
Abstract
The present invention relates to a renewable energy system designed to harness hydrokinetic energy from riverine environments using bio-inspired hydrofoil mechanisms. The system comprises a pair of hydrofoils configured to oscillate out-of-phase in response to water flow, a mechanical motion rectifier to convert oscillatory motion into unidirectional rotary motion, and a generator to produce electrical energy. A support structure stabilizes the components, while a control system optimizes energy generation by adjusting hydrofoil pitch angles and oscillation parameters based on sensory feedback. This innovative approach offers a scalable, efficient, and environmentally friendly solution for riverine hydrokinetics, minimizing ecological impact and adapting to varying site conditions.
A differential extraction device includes a first fluidic layer, a second fluidic layer, and a valving layer disposed between the first and second fluidic layers and include multiple chambers and microfluidic channels. The valving layer provides the ability to selectively allow and prevent flow between various chambers. Reagent chambers deliver reagent to a sample chamber and multiple recovery chambers receive material from the sample chamber. The valving layer provides the ability to selectively allow and prevent flow between various chambers.
C08G 65/48 - Polymers modified by chemical after-treatment
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
A computer implemented method for controlling insulin dosing for a subject includes saving field collected glucose and insulin data for the subject. The method implements a virtual personal model, or digital twin, of the subject by using the field collected data to save electronic field collected traces of blood glucose levels and electronic field collected traces of insulin levels for the subject. A replay phase of the virtual personal model emulates test insulin therapies to generate virtual insulin doses that correspond to the field collected data. The method converges to a result by comparing field collected glucose traces and regenerated glucose traces. This method recommends a basal rate profile for the subject using saved replay data by calculating inversions of the virtual personal model by deconvolution.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
Described herein are devices, systems, kits, and methods for, among other things, providing UV-C irradiation to central lines that are utilized to administer aqueous therapeutics that are delivered intravenously to a subject.
A flexible system for utilizing data from different monitoring techniques and capable of providing assistance to patients with diabetes at several scalable levels, ranging from advice about long-term trends and prognosis to real-time automated closed-loop control (artificial pancreas). These scalable monitoring and treatment strategies are delivered by a unified system called the Diabetes Assistant (DiAs) platform. The system provides a foundation for implementation of various monitoring, advisory, and automated diabetes treatment algorithms or methods. The DiAs recommendations are tailored to the specifics of an individual patient, and to the patient risk assessment at any given moment.
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
15.
NAD(H) NANOPARTICLES AND METHODS OF REDUCING VEIN GRAFT INJURY AND IMPROVING VEIN GRAFT HEALTH
The present technology provides methods of reducing vein graft injury comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the vein to be grafted prior to surgical implantation of the vein graft in a subject. Additionally, the present technology provides methods of improving vein graft health and preventing or treating post-operative restenosis and also provides bioavailable nanoparticles comprising NAD+ and/or NADH and a coating comprising a human cell membrane for use in such methods.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C04B 28/18 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing mixtures of the silica-lime type
Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some embodiments, the methods include administering to the subject a vector that has a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target cell and/or tissue. In some embodiments, the target cell and/or tissue can be a cell and/or tissue undergoing a stress response. In some embodiments, the target cell and/or tissue can be a cell and/or tissue in which a CK2 kinase is active. The kinase activity can be elevated extracellular regulated kinase (ERK) activity, p38 MAP kinase activity, and/or CK2 activity.
To address most recurrent pathogenic mutations associated with SCN8A-related epileptic encephalopathy, disclosed herein are SCN8A-targeting adenine or cytosine base editors designed to correct the following clinically relevant SCN8A gene variants: R1872W, R1872Q, R1617Q, R850Q, N1877S, and G1475R. By targeting these six recurrent genetic mutations, a personalized gene therapy solution for this type of pediatric epilepsy is provided.
Inline classification of a biological specimen including mammalian cells can include generating an alternating current (AC) electrical stimulus to an electrode structure. The electrode structure can be electrically coupled with a flow cell. A response, elicited by the electrical stimulus, can be received when a model specimen class traverses the flow cell. Using the received response, a corresponding impedance parameter value can be determined, the value indicative of a specified biophysical characteristic corresponding to the model specimen class. The first impedance parameter can be translated to a value corresponding to the specified biophysical characteristic.
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.
Provided are compositions that include single cell suspensions of pancreatic islet cells, pancreatic islet-like cells derived from iPS cells, or combinations thereof, wherein the cells are present within a MAP scaffold and/or are encapsulated by MAPs. In some embodiments, the MAP scaffold and/the MAPs have a polymer backbone that includes poly(ethyleneglycol) (PEG), hyaluronic acid, polyacrylamide, polymethacrylate, alginate, collagen, or any combination thereof. Also provided are methods for using the presently disclosed compositions for treating Type 1 diabetes, for example by administering to a subject with Type 1 diabetes such a composition via a route and in an amount effective for treating the Type 1 diabetes in the subject. In some embodiments, the administering includes injecting the composition into a kidney capsule, subcutaneously, intraperitoneally, into adipose tissue, intramuscularly, intrahepatically, and/or intrapancreatically into the subject.
A computer implemented method of reconstructing magnetic resonance images (MRI) in Cartesian coordinates uses acquired magnetic resonance data and implements a Fourier transform to place the MRI data in k-space. The method allows for under-sampling the k-space and achieving an accurate output image by selecting an image model to map the sampled data and iteratively converge the model to an output that matches a region of interest subject to the MRI. The image model may be an alternating direction method of multipliers (ADMM) or an ADMM with non-convex low rank regularization algorithm. A de-noising algorithm may be at least one of a plug and play block matching and 3D filtering (PnP-BM3D), a plug and play weighted nuclear norm minimization (WNNM), or a plug and play denoising convolutional neural networks (PnP-DnCNN) algorithm. An iterative optimization of the variables of the model yields an output image.
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are linked to compounds including a plurality of boron isotopes, e.g., carboranes such as 1-amino-1-carbadodecaborate. Compounds of the present disclosure were demonstrated to deliver eleven boron-11 atoms per dye molecule selectively to breast cancer cells. Upon irradiation with proton or neutron beams and subsequent nuclear fusion reaction by proton capture, unstable 12C is generated in place of 11B, which is short lived and releases high energy alpha particles. There particles travel only a short distance within cell and/or a very close tumor microenvironment, damaging cellular DNA ultimately resulting in killing cancer cells, and are particularly useful with young patients and with deep tissue tumors located in critical organs which are difficult to remove by surgery.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Various processes, algorithms, and systems are provided herein for assisting physicians in distinguishing among related diseases, such as distinguishing connective tissue associated interstitial lung disease from idiopathic pulmonary fibrosis. Methods for generating such processes, algorithms, and systems are also disclosed. In some embodiments, a preliminary diagnosis of a set of possible diseases is obtained, along with protein count information from a patient's blood sample. Additional, patient-specific information (e.g., age, sex, etc.) may also be obtained. The data is processed by a trained machine learning algorithm, to output a differential diagnosis of which of the set of possible diseases is present for that patient. Based on the diagnosis, a treatment course can be selected, and further information can be tracked regarding the patient's outcome.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/08 - Measuring devices for evaluating the respiratory organs
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
According to various aspects, an electrochemical storage device includes an electrode. The electrode includes TiNb2O7, LiCoO2, LiNi0.5Mn0.5O2, lithium metal, LiMn2O4, Li4Ti5O12, a mixture of LiMn2O4 and LiCoO2, or mixture thereof.
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
26.
SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR DIAGNOSING AN INDIVIDUAL'S PERSONAL SALT INDEX
Described herein are systems, methods, and computer readable medium for, among other things, determining an individual's personal salt index. Such systems, methods, and computer readable medium can be utilized for providing information that can help guide healthcare providers by making informed decisions about treatments based on the individuals salt index. Such informed decisions can help mitigate the worsening or possibility of an adverse cardiovascular event in an individual whose salt index is unknown and receiving a treatment modality that may not be suitable for their particular genotype, phenotype, or any combination thereof. An aspect of the present disclosure also provides a system, method and computer readable medium for, among other things, algorithms/models that enabled the determination of a individual salt index to enable the therapeutic intervention. Also described herein are compositions, pharmaceutical compositions, kits, and methods of administration relating to therapeutics for blood pressure normalization and/or pathological cardiovascular diseases/phenotypes.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
27.
METHOD AND SYSTEM FOR ALL-AQUEOUS PRINTING OF VISCOELASTIC DROPLETS
This document describes printing viscoelastic material in an aqueous medium. Such printing can involve positioning a print nozzle at specified coordinates in the medium and triggering deposition of the viscoelastic material to form a viscoelastic droplet. The deposition can be established by delivering a specified flow velocity of the viscoelastic material through an aperture in the print nozzle. The print nozzle can be detached from the droplet and a receiving material by translating the nozzle relative to the droplet according to a specified acceleration. The droplet can remain captive on or within the receiving material upon detachment from the nozzle.
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
Disclosed is a method of treating lung injury in a patient comprising providing a therapeutically effective amount of a pharmaceutical agent that enhances peroxisome biogenesis to a patient. The method includes increasing the number of peroxisomes in alveolar macrophages, decreasing peroxisome degradation, and improving peroxisome function in alveolar macrophages. Increasing the number and function of peroxisomes in alveolar macrophages promotes healing of lung injury and regeneration of alveolar epithelial. The lung injury may be due to infection, including viral infection, such as SARS-CoV-2 infection or influenza infection. The lung injury may also be due to exposure to caustic substances, tobacco smoke, asbestos, or fine particulate matter.
The present disclosure provides for compounds including derivatives of haloperidol, pharmaceutical compositions including haloperidol derivatives, methods of use of the haloperidol derivatives and their pharmaceutical compositions, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more therapeutic agents for treating inflammatory arthritis, gout, or other inflammation-related diseases or conditions.
An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
31.
SYSTEMS AND METHODS OF PROCESSING BRINE TO CAPTURE LITHIUM IONS
The present disclosure provides for methods and systems for processing brine to obtain lithium. The present disclosure provides for methods that leverages intercalation materials and drives lithium capture using a chemical approach to treating brine as opposed an electrochemical approach, which can be complicated and expensive. The present disclosure provides for a chemical redox-driven approach to selectively extract Li+ from brine.
ii = 82 nM, 122-fold SphK2 selective) with validated in vivo activity. Modifications to the guanidine head of the inhibitor provided compounds that were effective in alleviating the observed poor oral bioavailability.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.
Provided are methods and compositions for treating and/or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and/or preventing C. difficile infections include in some embodiments at least one agent that inhibits an alpha 2 adrenergic receptor, and the presently disclosed methods include administering at least one such composition to a subject in need thereof, optionally in combination with other therapeutically active agents including but not limited to an enhancer of an IL-13 biological activity, optionally an IL-13 peptide or a fragment or homolog thereof; an interleukin-13 receptor subunit alpha-2 (IL-13Ra2) inhibitor; an enhancer of an Interleukin-33 (IL-33) biological activity, optionally an IL-33 polypeptide or a biologically active fragment or homolog thereof; or any combination thereof.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Various technological aspects of functional tremor retrainment are described. For example, a mobile device may measure a baseline tremor frequency, determine a cue frequency based on the baseline tremor frequency, provide motion cues at the cue frequency, measure a motion frequency while providing the motion cues, and provide a feedback signal indicative of a synchrony of the motion frequency to the cue frequency.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
A63B 71/06 - Indicating or scoring devices for games or players
38.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
39.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
40.
BIFUNCTIONAL IL-2 AND IL-33 PROTEINS FOR TREATING AUTOIMMUNE DISEASE
The present invention provides, among other things, compositions and methods for prophylaxis and treatment of autoimmune disease. The present invention provides, in part, bifunctional proteins comprising interleukin-2 (IL-2) and interleukin-33 (IL-33) variants having increased manufacturability and activity, which synergistically expand or stimulate tissue targeting or reparative regulatory T cells. The present invention provides compositions and methods for proliferation and activity of ST24+ regulatory T cells.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
41.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The present invention provides, among other tilings, improved interleukin-33 (IL-33) variants engineered for increased manufacturability and activity, for example, mutated at one or more of N60, C116, C97, C121 or C148 relative to a truncated IL-33. The present invention also provides a. multifunctional fusion protein comprising an IL-33 variant associated with an IL-2 polypeptide and optionally, a half-life extension moiety. The present invention further provides compositions and methods for proliferation and activity of ST2+ regulatory T cells, for prophylaxis and treatment of autoimmune disease.
The present invention provides, among other things, compositions and methods for prophylaxis and treatment of cancer and other diseases. The present invention provides, in part, a bifunctional protein comprising an IL-2 variant biased to IL-2Rβ, and an interleukin- 33 (IL-33) variant engineered for increased activity and/or manufacturability. The present invention, for example, provides IL-2 variants mutated at one or more of F42, L80, R81, L85, 186 or 192 relative to wild-type IL-2 associated with IL-33 variants mutated at one or more of N60, Cl 16, C97, C121 or CMS relative to a truncated IL-33, that preferentially expands T effector cells. The present invention, among other things, provides a bifunctional fusion protein, optionally linking an IL-2 variant biased to IL-2Rβ, and an interleukin-33 (IL-33) variant via a linker, that preferentially expands T effector cells.
Apparatus and techniques described herein can include or use a rotationally-driven microfluidic assembly. For example, a sample can be propelled to a sample recovery chamber from a sample chamber using a gas evolved from a reaction between the liquid reagent and a dry reagent. Such gas evolution can provide displacement of a sample liquid or other liquid in an inward direction, such as proximally toward a center of rotation. Such gas evolution can include features or reagents, or both, that are compatible with downstream nucleic acid amplification tests.
Iowa State University Research Foundation, Inc. (USA)
Inventor
Zhang, Sen
Yin, Zhouyang
Qi, Long
Huang, Wenyu
Yu, Jiaqi
Abstract
The present disclosure provides for hybrid catalysts, methods of converting CO2 to C2 products (e.g., ethylene), systems for converting CO2 to C2 products (e.g., ethylene), and the like. The hybrid catalyst of the present disclosure effectively uses two steps of converting CO2 to ethylene in a single hybrid catalyst.
C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
A method can include receiving a biological sample including the target cells, e.g., at an inlet of a microfluidic structure. This can involve flowing the target cells, e.g., suspended in a first buffer, at a first flow rate within a main channel of the microfluidic structure. At least one focusing flow can be applied to the biological sample, using a second buffer at a second flow rate, to help establish a boundary defining a central region or streamline. The central region can contain the target cells within the main channel and promote ion diffusion between the first and second buffers.
SLC2A11-MIFSLC2A11-MIF was identified that is present in nearly 50% of CRC samples but absent in non-cancer colon tissue. Disclosed herein is a method for diagnosing and treating cancers expressing this chimeric RNA and protein.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
Provided are a method, system, and computer-readable medium for personalizing titration measurement for basal insulin dosing. The personalization can be achieved using spare self-monitoring blood glucose (SMBG) and/or dense continuous glucose monitoring (CGM) data to predict a fasting blood glucose (FBG) envelope accounting for online estimation of titration noise representative of variability in daily fasting measurement. As a result, basal insulin dosing directed to causing the FBG envelope to be maintained for an optimal glycemic range can then be obtained.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
51.
ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Hsu, Ku-Lung
Li, Zhihong
Abstract
Electrophilic purine-based compounds comprising mono- and di-halo-substituted purine moieties are described. The compounds also include acetamide substituents. The compounds are reactive in nucleophilic aromatic substitution reactions. The compounds generally showed the highest reactivity when a thiol was used as the nucleophile. Methods of using the compounds to covalently modify proteins containing nucleophilic side chains and/or to modulate protein activity are also described.
C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
53.
SYSTEMS AND METHODS FOR OPTIMIZATION OF RADIATION TREATMENT PLANNING TO IMPROVE IMMUNE RESPONSE
Systems and methods are provided for estimating immune response effected by patient specific and plan specific radiation treatments (such as, e.g., SBRT). The systems and methods may take into account radiation impact on circulating immune blood cell types or sub-types, such as T lymphocytes, B lymphocytes, natural killer cells, erythrocytes, and/or neutrophils, and predict time dependent fractional blood count and cell kill following radiation therapy treatment. Additionally, the system, method, and computer readable medium provide parameters such as a dose dependent lymphocyte kill function and average net release rate of new lymphocytes into circulating blood (including promotion of cytotoxic T cells and suppression of lymphocytes in blood), which may be used for optimization of RT treatment plans.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Various aspects of the instant disclosure provide a metal-organic framework- polymer composite organic-gel material. The material includes zirconium -based MOF (UiO-66) and multiple polymer components to form a gel network and exhibit multifunctionality (conductivity and piezoelectricity).
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
C08G 83/00 - Macromolecular compounds not provided for in groups
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
55.
ELECTRODES, BATTERIES INCLUDING THE ELECTRODES, AND METHODS OF MAKING BATTERIES
The present disclosure provides for electrodes, batteries that include the electrodes, method of making electrodes and the like. The present disclosure provides for electrodes that are thicker than typical electrodes that have a higher energy density at the cell level, regardless of the specific cell chemistry. The electrodes are all active material (AAM) electrodes (e.g., AAM anodes and AAM cathodes). In an aspect, the electrodes of the present disclosure have improved ion transport in the electrode microstructure and the concomitant reduced tortuosity and improved retention of electrochemical capacity at increased cycling rates.
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01G 11/24 - Electrodes characterised by structural features of the materials making up or comprised in the electrodes, e.g. form, surface area or porosityElectrodes characterised by the structural features of powders or particles used therefor
H01G 11/60 - Liquid electrolytes characterised by the solvent
H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
56.
SYSTEMS AND METHODS RELATED TO COMPETITION AND MUTUALISM IN THE DYSBIOTIC VAGINAL MICROBIOME
Described herein are systems, methods, and computer readable medium for, among other things, predictive platforms for novel microbial therapeutics. Such systems, methods, and computer readable medium can be utilized for identifying candidate therapeutics and/microbiota for administration against a candidate bacterial infection in particular. In embodiment, the bacterial infection is bacterial vaginosis. An aspect of the present disclosure also provides a system, method and computer readable medium for, among other things, algorithms/models that enabled the predictions of the specific combinations of bacteria and putative therapeutic targets to enable the therapeutic intervention.
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and/or assessing risk of PNAC in a subject, including screening a sample from a subject believed to be at risk for PNAC for one or more biomarkers of PNAC. The biomarkers can include one or more fecal metabolites. Such biomarkers and associated methods provide neonatal intensive care unit clinicians with an additional tool for early identification of PNAC risk. Early identification of high-risk infants would enable clinicians to confidently optimize caloric nutrition with PN for infants at low risk of developing PNAC and enable proactive mitigation with alterations to the administered PN.
In one aspect, the disclosure relates to an apparatus comprising: a plate; a plurality of wells set into the plate, wherein each individual well of the plurality of wells extends from an outer surface of the plate to an inner surface of the individual well; and a plurality of hydrogels, wherein at least two individual wells of the plurality of wells each comprise a singular hydrogel of the plurality of hydrogels; wherein each individual hydrogel of the plurality of hydrogels comprises a dithiol crosslinker and a first backbone polymer functionalized with an alkene; and wherein at least one hydrogel of the plurality of hydrogels is different from the remaining hydrogels of the plurality of hydrogels. Also disclosed herein are methods of fabricating the apparatus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the disclosure.
Disclosed are various approaches for bit-serial computing embedded in the DRAM subarray, leveraging the massive parallelism of DRAM row operations. The present disclosure discloses digital techniques that can outperform analog charge-sharing techniques. Digital techniques can use more area but support a wider range of computing primitives, and allow a sequence of logic operations to be performed at higher clock speeds, be-tween slower subarray row reads/writes. The present disclosure describes a range of bit-serial architectures, and evaluate raw performance as well as area and energy efficiency. Results show that the digital architecture demonstrates 20× speedup over CPU, 5× over GPU, and 1.7× over SIMDRAM, an analog architecture.
Systems and methods of generating music that encodes personalized information implement and/or include generating a personalized sonification model based on music modeling data pertaining to a user; receiving physiological data pertaining to the user, wherein the physiological data is related to at least one of a physical wellness or a behavioral wellness of the user; generating a melody, wherein the melody encodes a wellness information or modification based on the personalized sonification model and the physiological data; and providing the melody to the user to convey the wellness information or modification.
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The capillary transfer technology presented here represents a powerful approach to transfer soft films from surface of liquid onto a solid substrate in a fast and defect-free manner. The fundamental theoretical model and transfer criteria validated with comprehensive experiments and finite element analyses, for the first time provides a quantitative guide and optimization for the choice of material systems, operating conditions and environments for scalable on-demand transfers with high yield. The intrinsically moderate capillary transfer force and externally selectable transfer direction offer robust capabilities for achieving deterministic assembly and surface properties of structures with complex layouts and patterns for potentially broad applications in the fabrication of flexible/stretchable electronics, surface wetting structures and optical devices. Integration of this technology with other advanced manufacturing technologies associated with material self-assembly, growth and layout alignment represents promising future topics and would help create emerging new manufacturing technologies that leverage unique fluidity of liquid environments.
H05K 3/20 - Apparatus or processes for manufacturing printed circuits in which conductive material is applied to the insulating support in such a manner as to form the desired conductive pattern by affixing prefabricated conductor pattern
Provided are embodiments of a device, having a device body suitable to hold a syringe. The device body can have an elongated member with a distal support and a proximal support. The device further includes a ratcheting rod configured to fit moveably within an open chamber in the elongated member, where the ratcheting rod has a proximal end configured to connect to a plunger of the syringe. The device can include a lever handle hingedly connected to a distal end of the device body, and a ratcheting lever hingedly connected to a distal end of the lever handle and positioned to interact with the ratcheting rod. Compression of the lever handle forces the ratcheting lever to extend the ratcheting rod in a proximal direction and to extract the plunger of the syringe.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
64.
FERROELECTRIC MIXED METAL OXIDE FILMS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME
(1-x)x(2-y)(2-y) (1) where M is zirconium, cerium, aluminum, silicon, lanthanum, yttrium, strontium, gadolinum, strontium, gallium, calcium, magnesium, or a combination thereof; where x is 0.05 to 0.95 and where the mixed metal oxide film is formed in the presence of a plasma; where the plasma is formed in an atmosphere that comprises nitrogen and oxygen in a molar ratio of 0.5:1 to 10:1; and where y is 0 to 0.5.
The present disclosure provides for graphene hybrid materials, methods of making graphene hybrid materials, batteries, methods of making batteries, methods of using batteries, shielding including the graphene hybrid materials, and the like. In an aspect, the graphene hybrid material is a carbon nanotube/graphene hybrid material, where the carbon nanotubes are grown on the surface of the graphene.
dd(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
67.
CARD9 ATTENUATES AB PATHOLOGY AND MODIFIES MICROGLIAL RESPONSES IN AN ALZHEIMER’S DISEASE
Provided herein are methods and compositions to enhance or activate protective microglial activities (such as phagocytosis of neurotoxic material) by activating CARD9.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
68.
METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
69.
SYSTEM AND METHOD FOR MACHINE LEARNING FOR UNIVERSAL PHOTONIC QUANTUM COMPUTING RESOURCES
The present disclosure presents systems and methods for implementing a quantum error correction code with quantum light. One such method comprises iteratively training, by a computing system using reinforcement learning, at least one neural network that is interacting with a model of a measurement-based quantum optical circuit to generate circuit parameters for the measurement-based quantum optical circuit, wherein the generated circuit parameters produce a target optical quantum state of the measurement-based quantum optical circuit; applying the generated circuit parameters to the measurement-based quantum optical circuit; and/or outputting a quantum state of the measurement-based quantum optical circuit.
G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
G06F 11/08 - Error detection or correction by redundancy in data representation, e.g. by using checking codes
Disclosed herein is a biosensor fusion protein comprising an N-terminal half of a human liver fatty acid binding protein (hLFABP) and a C-terminal half of the hLFABP separated by a circularly permuted fluorescent protein (cpFP), wherein the binding of the N-terminal half of the hLFABP and the C-terminal half of the of the hLFABP to a per- or polyfluoroalkyl substance (PFAS) elicits a change in fluorescence of the cpFP. Also disclosed method for detecting per- and polyfluoroalkyl substances (PFAS) in a sample, comprising contacting the sample with the biosensor disclosed herein, assaying the sample for fluorescence, wherein an increase in fluorescence is an indication of the presence of PFAS. In some embodiments, the PFAS is perfluorooctanoic acid (PFOA). In some embodiments, the sample is a water sample.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present disclosure provides for double-network hydrogel particles, methods of making double-network hydrogel particles, methods of making objects (e.g., three-dimensional objects) using double-network hydrogel particle, and the like. In an aspect, double-network hydrogel particles are viscoelastic voxels (e.g., spherical or semi-spherical) that can be precisely manipulated in three-dimensional space and can be used in both soft matter science and biomanufacturing. The present disclosure provides for a voxelated bioprinting technology that enables the digital assembly of interpenetrating double-network hydrogel particles to form objects, in particular three-dimensional objects.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
73.
REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION
Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.
The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.
The present disclosure presents systems and related methods of programming with concepts. One such method comprises implementing, by a computing device, at least one concept of an application as a full-stack concept codebase, wherein syntax and semantics of the concept codebase are generated using an available programming language; organizing, by the computing device, concept codebases into one or more codebase directories; and/or composing, by the computing device, a plurality of concept codebases from the one or more codebase directories into a larger concept codebase using composition operators to build a complete concept-based full-stack application system.
Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
77.
SYSTEM AND METHOD FOR DISPLACEMENT AND STRAIN DETECTION USING COLOR TRACKING
Optical inspection systems, methods, and media are configured to perform and/or implement, for a plurality of image frames of a target object captured by an image sensor, the target object including at least one fiducial marker: receiving a respective image frame, the image frame including an n-dimensional array of pixel values corresponding to a plurality of colors, converting the image frame to a color-adjusted image, the color-adjusted image including a two-dimensional array of pixel values corresponding to a first color of the plurality of colors, and determining at least one centroid corresponding to at least one region in the color-adjusted image tracking the at least one centroid across at least two of the plurality of image frames; and outputting an indication of a mechanical parameter of the target object based on the tracking.
Optical inspection systems, methods, and media are configured to perform and/or implement receiving a time series of 3D point cloud images of a target object from an imaging system, wherein the 3D point cloud images include first directional position data, second directional position data, and change in first directional velocity data; applying a self-supervised machine learning model to the time series of 3D point cloud images, wherein the trained machine learning model has been trained on a plurality of training point cloud images to which simulated cracks have been added; and identifying a mechanical failure in the target object based on an output of the machine learning model.
The Royal Melbourne Institute of Technology (Australia)
Inventor
Eaton, Miller Thomas
Gonzalez-Arciniegas, Carlos
Pfister, Olivier
Alexander, Rafael
Menicucci, Nicolas
Abstract
Methods are disclosed for generating, manipulating, and controlling non-Gaussian quantum states in continuous variable cluster quantum states usable for quantum computing. Some methods can be used to generate, transport, and enlarge Schrödinger-Cat states embedded in the CV cluster quantum state. Some methods can be used to transform Schrödinger-Cat states embedded in the CV quantum cluster state to grid states (such as Gottesman-Kitaev-Preskill states) and enlarge the grid states. In certain embodiments, some of the methods may be used to generate and control non-Gaussian states in macronode cluster quantum states such as cluster states comprising two-mode macronodes.
The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to image reactive oxygen and nitrogen species (RONS). The disclosed compounds and pharmaceutical compositions can also be useful in treating diseases or disorders due to oxidative stress or otherwise based on RONS pathophysiology such as, for example, neurological diseases, cancer, cardiovascular diseases, and ischemia reperfusion injury (IRI). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A system and method of forming an article include floating a pliable material onto a liquid held in a bath structure and placing a curvilinear substrate into the bath structure with the substrate having at least clockwise and counterclockwise rotational degrees of freedom, relative to a lengthwise axis of the substrate, within the liquid. A lateral edge of the pliable material is in contact with an outer surface of the curvilinear substrate to define a transfer front at an intersection of the lateral edge and the curvilinear substrate, and rotation of the curvilinear substrate advances a leading longitudinal edge of the pliable material onto the curvilinear substrate from the transfer front at an initial orientation angle, alpha (α), and an advanced orientation angle, beta (β), relative to the transfer front.
B29C 53/12 - Bending or folding helically, e.g. for making springs
B29C 53/40 - Bending and joining, e.g. for making hollow articles by bending sheets or strips at right angles to the longitudinal axis of the article being formed and joining the edges for articles of definite length, i.e. discrete articles
B21C 37/12 - Making tubes or metal hoses with helically arranged seams
A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
83.
POLYMERS, POLMER NETWORKS, AND METHODS OF MAKING POLYMER NETWORKS
The present disclosure provides for foldable bottlebrush polymers, foldable bottlebrush polymer networks and methods of making foldable bottlebrush polymers and foldable bottlebrush polymer networks. The present disclosure provides a general method for decoupling stiffness and extensibility of polymer networks. Instead of using classical linear polymers as network strands, an aspect of the present disclosure provides for methods using foldable bottlebrush polymers, which feature a collapsed backbone grafted with many linear side chains. Upon elongation, the collapsed backbone unfolds to release stored length, enabling remarkable extensibility. By contrast, the network elastic modulus is inversely proportional to the network strand mass and is determined by the side chains.
C08F 290/02 - Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
85.
SYSTEM AND METHOD FOR AUTONOMOUS ROBOTIC MAP GENERATION FOR TARGETED RESOLUTION AND LOCAL ACCURACY
Various examples are provided related to generating a map of an environment. In one example, a method includes obtaining a coarse global mapping of an environmental space; determining a robotic traversal path within the environmental space using the coarse global mapping, the robotic traversal path maintaining a targeted distance to a nearest structure within the environmental space; initiating traversal of a robot along the determined robotic traversal path, the robot obtaining depth sensor measurements of the nearest structure during traversal along the determined robotic traversal path; and refining the robotic traversal path during traversal by the robot along the determined robotic traversal path based upon the depth sensor measurements, where the robotic traversal path is refined online to achieve targeted resolution and local accuracy of the depth sensor measurements. A refined map of the environmental space can be generated using the depth sensor measurements.
A fully autonomous self-powered system-on-chip (SoC) that can be distributed along a fiber strand, capable of simultaneously harvesting energy, cooperatively scaling performance, sharing power, and booting-up with other SoCs in-fiber. In some examples, a system includes at least one textile fiber comprising an embedded electrical bus. The system includes a number of SoCs electrically coupled by the embedded electrical bus. Each SoC comprises at least one processor and an energy harvesting and power management unit (EHPMU) configured for power sharing and cooperative dynamic voltage and frequency scaling (DVFS) with the other SoCs.
Disclosed are various embodiments for validating crowdsourced flood images using machine learning and real-time weather data. Various embodiments can obtain a weather event upload request from a client device that includes an upload geolocation and an image. Various embodiments can direct a convolutional neural network (CNN) model to predict flood activity within the image. Next, various embodiments can obtain weather data corresponding the upload geolocation from a weather application programming interface (weather API). When various embodiments determine that the weather data indicates flood conditions for the upload geolocation, various embodiments can publish the image and the upload geolocation into a plurality of flood activity images for the upload geolocation.
The present disclosure is directed an air-liquid-interface culture apparatus including a porous support and a polyacrylamide hydrogel layer. The porous support includes a polymer plate having a plurality of pores and a support surface. The polyacrylamide hydrogel layer is deposited onto the support surface of the porous support. The polyacrylamide hydrogel layer includes a polyacrylamide hydrogel having mechanical properties that mimic the extracellular matrix for epithelial cells in the human airway. An air-liquid-interface cell culture system disclosed herein may include the air-liquid-interface culture apparatus disclosed herein with one or more cells deposited on the polyacrylamide hydrogel layer.
A method of forming a lanthanide or transition metal doped metal halide perovskite material whereby the method includes combining a monovalent metal cation-halide compound, a divalent metal cation-halide compound, and a lanthanide or transition metal halide compound in a solvent; evaporating the solvent to form a powder; and annealing the powder to form the lanthanide or transition metal doped metal halide perovskite material. The resultant materials or devices may be applied to various industrial applications or implemented as a scintillator and applied to various industrial applications.
An exemplary method and system is disclosed that facilitate the integration of multiplexed single-cell impedance cytometry in a high throughput format, which can be deployed upstream from microfluidic sample preparation and/or downstream to microfluidic cell separation. In exemplary method and system may employ impedance-based quantification of cell electrophysiology on the same microfluidic chip (i.e., “on-chip”) to provide distinguishing phenotypic information on the sample, without the need for additional sample handling, preparation or dilution steps as would be needed for other flow cytometry techniques.
Systems and techniques for compressed air energy storage and regeneration thereof are described herein. A compressor for compressed air energy storage and regeneration thereof can include a housing, a actuator, and a heat exchanger. The housing can define a volume. The actuator can be operable to expand the volume and compress the volume. The heat exchanger can be located at least partially within the housing. The heat exchanger can be configured to compress when the actuator compresses the volume, expand when the actuator expands the volume, and transfer heat with a working fluid.
A system for increasing power capture comprising a turbine having a rotor, a generator having a rated power limit, and an energy storage system, wherein the rotor generates a super-rated power above the rated power limit of the generator and the super-rated power is stored in the energy storage system before the generator converts the super-rated power into electric power.
A method for treatment of a patient suffering from a cancer, an autoimmune disease, an infection, a neurodegenerative disease or any combination thereof is disclosed. Compositions and uses are also disclosed. The method includes providing fresh immune effector cells (IECs) armed with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh IECs; and administering an effective amount of a composition of cells to the patient, wherein the composition of cells comprises the multispecific antibody bound fresh IECs. The fresh IECs cab comprise a cell selected from the group consisting of peripheral blood mononuclear cells (PBMC), antigen-presenting cells. T cells (optionally fresh Bi Ab armed T cells (FBATs)). NK cells, monocytes, polymorphonuclear neutrophils (PMNs), and any combination thereof. Providing the fresh IECs can comprise isolating fresh IECs from the patient. Arming fresh IECs can be accomplished with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh IECs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
95.
STEADY-STATE THERMO-REFLECTANCE METHOD & SYSTEM TO MEASURE THERMAL CONDUCTIVITY
A method of measuring thermal conductivity of a material includes aiming a modulated pump laser beam having a modulation frequency low enough to induce a cyclical steady-state temperature rise having “on” and “off” state at a spot of a material, aiming a CW probe laser beam at the spot and generating a reflected probe beam reflected from the spot on the material, the reflected probe beam having a magnitude of a reflectance signal as a function of the temperature of the material and being periodic corresponding to the cyclical temperature rise, measuring the pump power difference and the reflectance signal magnitude difference between the “on” and “off” states, and calculating the thermal conductivity by fitting the measured power difference and the measured reflectance signal magnitude difference to a thermal model which is a function of a thermal conductivity of the material relating the heat flux to the temperature rise.
G01N 25/20 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
96.
SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS
Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. The compounds can form covalent adducts with reactive nucleophilic amino acid residues, e.g., reactive tyrosines and reactive lysines, in kinases to form modified kinases and/or alter the biological activity of the kinases. Kinases targetable by the compounds include cyclin-dependent kinase 2 (CDK2), diacylglycerol kinases (DGKs), and phosphofructokinase (PFK). Pharmaceutical compositions including the compounds and methods of inhibiting kinases are also described.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A wireless charging station installed on the seafloor is equipped with multiple wireless transmitter coils and powered by a large-capacity lithium-battery-based energy storage system (ESS). Correspondingly, small-size wireless receiver coils are installed inside underwater robots and vehicles. When the battery is low in the underwater devices, the robots and vehicles automatically swim to the charging station and land in a specific charging region. After identifying the robots and vehicles, the wireless charging station can automatically start a wireless charging operation.
H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
B60L 53/126 - Methods for pairing a vehicle and a charging station, e.g. establishing a one-to-one relation between a wireless power transmitter and a wireless power receiver
Embodiments disclosed herein provide methods of making polymer-metal organic framework-gels (polymer-MOF-gels), the method comprising forming a metal solution comprising a metal salt, an acid, and a first solvent, and forming a product mixture comprising the metal solution, a polymer, and a carboxylic acid linker to produce the polymer-MOF-gel. Embodiments disclosed herein provide polymer-MOF-gels comprising a polymer and a metal organic framework (MOF) having pores, wherein at least a portion of the polymer is entrapped in the pores of the MOF.
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
Characterizing the latent heat of fusion of a sample material can involve irradiating the sample material with laser light generated by a first laser, which includes elevating the temperature of the material to induce a phase transition between solid and liquid states. The method can also include measuring a property of the sample material during thermal arrests, which occur when the material transitions between these states. The composition of the sample material can be determined, e.g., by utilizing values corresponding to the amount of energy delivered to the sample material by the laser light and the properties measured during the thermal arrests.
